Back to results
US 2002/0165274 A1Published application
Use of aryl nitrone compounds in methods for treating neuropathic pain
AssigneeRenovis, Inc.
InventorsL. David Waterbury, Paul L. Wood, M. Amin Khan, Ravindra B. Upasani
Life of this patent
Estimating the term…
Abstract
3,4,5-trisubstituted aryl nitrone compounds having the formula: 1 where R1—R4 are as defined in the specification are useful as therapeutics for neuropathic pain conditions in mammals.
Claims35
A method for treating neuropathic pain is a patient comprising administering an effective neuropathic pain-treating dose of a pharmaceutical composition comprising a compound of formula I:
- 15
- R1 is selected from the group consisting of hydrogen, alkyl
- 16
- each R2 is independently selected from a group of the formula:
- 17
- R3 is selected from the group consisting of hydrogen, alkyl, cycloalkyl and aryl;
- R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R6 and R7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R6 and R7 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R8 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R8 and R9 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl;
- or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)— —S(O)— or —S(O)2— group;
- R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl;
- or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
- X is oxygen, sulfur, —S(O)— or —S(O)2—;
- and
- W is oxygen or sulfur;
- and pharmaceutically-acceptable salts thereof.
18 more elements
A pharmaceutical composition for the treatment of neuropathic pain comprising a pharmaceutically acceptable carrier and a pharmaceutically effective neuropathic pain-treating amount of a compound of formula I:
- 22
- wherein
- R1 is selected from the group consisting of hydrogen:
- 23
- each R2 is independently selected from a group of the formula:
- 24
- R3 is selected from the group consisting of hydrogen, alkyl, cycloalkyl and aryl;
- R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R6 and R7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R6 and R7 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R8 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
- or R8 and R9 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
- R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl;
- or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)— —S(O)— or —S(O)2— group;
- R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl;
- or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
- X is oxygen, sulfur, —S(O)— or —S(O)2—;
- and
- W is oxygen or sulfur;
- and pharmaceutically-acceptable salts thereof.
19 more elements
Dependencies are inferred from the claim text.